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 Abstract 
Improvements in the physiological relevance of cell-based assays have been enabled by 
the development of various interdisciplinary methods. However, due to their complexity, 
in vivo structures such as basement membranes (BMs), which regulate the phenotype of 
adherent cells, are still difficult to mimic in vitro. The reconstruction of a physiologically 
relevant BM is crucially important to develop cell-based assays with the capacity for drug 
screening and disease modelling. Here, we review the biophysical and biochemical 
properties of BMs in vivo and their interactions with neighbouring cells. We discuss the 
current methods used to mimic BM functions in cell-based assays according to the type of 
targeted applications. In doing so, we examine the advantages and limitations of each 
method as well as exploring approaches to improve the physiological relevance of 
engineered or cell-derived BMs in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 I. Introduction 
Since the invention of the petri dish in 1887 by Julius Richard Petri1, there have been many 
improvements in cell culture approaches in order to reconstruct biologically and 
physiologically relevant cell-based assays, using interdisciplinary methods. These 
improvements have been achieved by the development of new technologies such as: (i) 
stem cells with both mesenchymal stem cells (MSCs)2 and induced pluripotent stem cells 
(iPSCs)3 (ii) microfluidics to control the cellular phenotype with chemical gradients4,5 or 
shear stresses6,7 and (iii) biomaterials, which regulate the microenvironmental cues.8,9 
However, these cell-based assays often lack relevant cell-extracellular matrix (ECM) 
interactions. This is particularly critical with assays aiming to recapitulate 
endothelial/epithelial tissues where cell phenotypes are regulated by the ECM from 
adjacent basement membranes (BMs).10  
 
BMs are thin layers of specialized ECM proteins, which have various fundamental 
functions: (i) to provide a structural scaffold to support endothelial or epithelial cells, (ii) 
to act as a barrier between tissue compartments and (iii) to maintain neighbouring cell 
phenotypes.11–13 These functions depend on the biophysical/biochemical properties of 
BMs, which change according to the localisation within the body.14 In this review, we 
discuss the properties of in vivo BMs induced by the core BM components (type IV 
collagen, laminins, nidogens and heparan sulphate proteoglycans).15–17 We highlight the 
impact of these properties on cellular phenotypes as well their modification due to 
disease.18–20 We, subsequently, describe the different methods used to mimic the BM, 
mainly in coculture systems, according to their properties from polymer membranes to 
cell-derived ECM.21–25 Finally, we conclude by comparing these methods according to the 
 targeted applications for cell-based assays, namely drug screening and disease 
modelling.26,27  
 
II. In vivo basement membranes 
In vivo BMs are very complex supramolecular assemblies formed by the interactions 
between two predominant  networks of ECM proteins, type IV collagen (formed by three 
α chains) and laminin (formed by α, β and γ chains).11,12 These networks are cross-linked 
by nidogens and interact with the heparan sulphate proteoglycans (e.g. agrin and 
perlecan).28 Moreover, BMs are connected to cell surface receptors such as integrins or 
dystroglycans. 29–32 The BM molecular assembly is illustrated in Figure 1.12,13,33 Besides 
the major components shown in Figure 1, various other molecules from the ECM are also 
present within the BM but in lower amounts, which makes it difficult to isolate and 
identify them. However, much recent progress has been made in this regard thanks to 
new “omics” technologies (genomics and proteomics) allowing for the characterisation of 
the matrisome.34–36 Proteomic studies have now reported the complexity of: (i) the renal 
glomerular ECM composition, where the presence of 144 structural and regulatory 
proteins has been revealed 37, (ii) the ECM secreted by bone marrow-derived and adipose-
derived MSCs 38, (iii) the ECM from decellularised rat liver 39 and others tissues.40  This 
complexity also applies to BMs.41  
a) Biophysical properties 
An  important biophysical characteristic of BMs is their thickness, which varies from 50 
to 100nm according to their localisation, as well as their composition.12,13 The mechanical 
stability of BMs is thought to be regulated by the type IV collagen network due to its 
unique structure and its abundance within BMs. This network is formed from a trimer of 
three α chains that bind together to form a triple helix and the trimers then assemble into 
 a network. The collagenous domains in the triple helix have hydrogen bonds and 
electrostatic interactions between the key residues (mainly glycine, proline and 
hydroxyproline) and these are likely to stabilize the molecule.42–44 The two terminal 
domains, 7S domain at the N-terminus and the non-collagenous NC1 domain at the C-
terminus also stabilize the network. This is achieved by the presence of cysteine and 
lysine residues, which crosslink the chains through disulphide bonds and 
lysine/hydroxylysine interactions at the N-terminus45 and by non-covalent bonds 
mediated by various ions46,47 and cross-linking formed via post-translational modification 
and sulphilimine bonds at the C-terminus.48,49 Moreover, these cross-links also contribute 
to the mechanical properties of BMs. A recent publication by Bhave et al. demonstrated 
that type IV collagen sulphilimine cross-links in NC1 domain contribute to these nonlinear 
properties.50 Moveover, these nonlinear properties are modified in peroxidasin knockout 
mice due to the reduction of sulphilimine cross-links.  It is important to note that the 
stability of the type IV collagen network can be modified according to type IV collagen 
isoforms, particularly in the glomerular BM.51 The independent laminin network also 
contributes to the BM stability because of its interactions with the neighbouring cells and 
its cross-linkage to the type IV collagen network with nidogen. Besides these two 
networks, the flexibility of the BM is also due the presence of perlecan, a heparan sulphate 
proteoglycan. This flexibility has been demonstrated to help the organ shaping in the 
drosophila.52  
 
BM biophysical properties regulate the cell phenotype through various cues: the BM 
topography and the BM mechanical properties (e.g. stiffness, shear-strain response)53,  
which depend on the BM structure. The BM topography is induced by the BM protein self-
assembly, which generates a fibrous scaffold from type IV collagen and laminin networks. 
 This scaffold exhibits specific patterns in term of size and geometry at the nanometre 
scale.54,55 As the previously described biophysical cues, these topographic features also 
depend on their localisation in the body and on the species as shown by ex vivo 
measurements.53 Inspired by the topographic features found in native vascular 
endothelial BMs, Liliensiek and co-workers generated substrates with: (i) anisotropically 
ordered ridge and grove structures and (ii) isotropically ordered pores from 0.2µm to 
2µm in size.56 Using different human endothelial cell lines, they demonstrated that all cell 
lines exhibit a highly pronounced orientation and alignment on anisotropically ridges 
equal or above 0.8 µm in size. Moreover, one cell line (human umbilical vein endothelial 
cells) showed a decreased proliferation on the smallest topographic features.  Along with 
this work, various reports have demonstrated that BM topographic features (size, 
geometry and isotropy) have a strong influence on the phenotypes of the overlying 
cells.57–59  
 
Besides the BM topography, the BM stiffness or, in other terms, its elastic modulus (i.e. 
Young’s modulus), plays an important role by regulating gene expression in response to 
mechanical cues by virtue of the links between the cytoskeleton and the ECM components 
via adhesion receptors.7,60 It has been demonstrated in vitro that cell fate is influenced by 
the elastic modulus of the substrate on to which the cells adhere.8,61 For this reason, cell 
behaviour is likely to be modulated by the Young’s modulus of a BM, which varies from 
1kPa to 2.57MPa according to the BM localisation.53,62 Furthermore, the ECM components 
forming BMs exhibit nonlinear mechanical properties and a shear modulus ~100Pa.63 
Two particular properties have been described in the literature: (i) a nonlinear stress-
stiffening observed on biological gels64,65 and (ii) a nonlinear shear stress-softening 
observed on decellularised normal and fibrotic rat liver.66 These examples of nonlinear 
 behaviour are typical of biological gels and cannot be reproduced using artificial polymers 
such as polyacrylamide. Furthermore, it also has been demonstrated that the BM 
mechanical properties strongly influence not only cell migration67 but also BM breaching 
through mechanical processes.68,69 Significantly, diseases targeting BM components can 
destabilize the BM structure (Table 1) and thus alter BM biophysical properties. 
  
 Figure 1: Structure of the in vivo basement membrane composed of two predominant 
networks of type IV collagen and laminin, respectively. These networks are cross-linked 
by nidogen and interact directly or through agrin and perlecan, with the cell receptors 
(e.g. integrins and dytroglycan). 
 
b) Biochemical properties 
Along with these biophysical features, the biochemical properties of the BM are essential 
for cellular regulation due to the BM components. These properties are involved not only 
in various functions regulating neighbouring cells, such as cell adhesion and cell 
phenotype, but also in the diffusion of macromolecules or ions from the external 
environment and BM remodelling. As illustrated in Figure 1, cell adhesion on BMs is 
controlled by different types of biochemical interactions between the major cell surface 
adhesion receptors (e.g. integrins, dystroglycans) and matrix ligands. These adhesion 
interactions can activate intra-cellular signalling pathways leading to altered cell motility 
or cell differentiation.70 Furthermore, it has been shown that laminin-integrin and 
laminin-dystroglycan binding are required to polarize the epiblast epithelium during 
early embryogenesis.32 These interactions between the cell adhesion receptors and the 
laminin network explain the important role of laminin in numerous signalling pathways 
(modulation of growth factors, migration and inflammation of immune cells) that change 
cell phenotype.29 The role of the laminin α subunits was studied during C. elegans 
development, showing that mutated α subunits disrupt BMs and lead to ectopic adhesion 
complex formation with downstream effects on cell-cell adhesion and cell signaling.71  
Furthermore, cell phenotype is also affected by various endogenous factors as BMs act as 
a reservoir for growth factors and release them according to biochemical stresses.17 These 
factors include fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF) and Von Willebrand factor.17 If laminin 
exhibits endothelial growth factor (EGF)-like domains, these growth factors are mainly 
 sequestered by the heparan sulphate proteoglycans (HSPGs). For example, perlecan is 
composed of 5 major domains with their own biochemical activities such as angiogenesis, 
growth factor and morphogen sequestration, lipid retention and cell surface binding.72  
Agrin is the dominant HSPG of the glomerular BM and plays an important role in 
neuromuscular junctions. Moreover, it contains domains that interact strongly with 
various growth factors.37,73,74 Besides these GF-like domains, the HSPGs have also another 
function in the biochemical properties of BM due to their sulphated lateral chains. As a 
result of their negatively charged groups, they control the interaction with cationic 
proteins and positively charged ions (diffusion of molecules and ions through the BM). 
The loss of these lateral chains can impair various biochemical functions of the HSPGs, the 
filtration properties of the BM and be linked to diseases.75,76  
 
Another important biochemical property arises from localized remodelling of the BM, 
which occurs during development, via controlled degradation to allow immune cells 
trafficking from the endothelium to the epithelium, and also during extravasation of 
metastatic cancer cells.28,77,78 This disruption and remodelling are triggered by two 
families of metalloproteinases, which cleave the ECM components: (i) matrix 
metalloproteinase (MMP) and (ii) a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS).79 Some fragments resulting from this degradation 
have been shown to have specific biochemical activities within the BM such as being anti-
angiogenic (e.g. endorepellin)17,72 or with other organs through the blood flow.80–82 
Furthermore, these biochemical properties depend strongly on the BM protein isoforms 
present within a particular tissue. The presence of the incorrect isoform or defects in the 
isoform structure can alter the BM properties as detailed in the Table 1. 
  
 Involved BM 
protein/chain in 
the disease 
Effects on the BM biophysical 
properties 
Effects on the BM 
biochemical properties 
Type IV collagen 
183 
Thin BM, disruption of the type 
IV collagen network 
Loss of cell adhesion 
Type IV collagen 
3, 4, 5 
chains18 
Thin BM, disruption of the type 
IV collagen network 
Loss of cell phenotype: 
(morphological change, high 
expression of matrix 
metalloproteinase) 
Type IV collagen 
3NC domain44 
Disruption of the type IV 
collagen network 
Activation of complement and 
proteases 
Laminin 
β2 chain84,85 
Defects in the laminin network Loss of cell phenotype 
(morphological change, 
decrease in the expression of 
specific markers), modification 
of EGF-like domains 
Laminin 
γ1 chain86 
Defects in the laminin network Modification of the EGF-like 
domains 
Perlecan87 Modification of the BM 
flexibility,  
Modification of the GF 
-like domains 
Agrin88 Disruption of the binding with 
the laminin network 
Disturbance of the biochemical 
activity in neuromuscal 
junctions 
 Nidogen-189 Disruption of the binding 
between type IV collagen and 
laminin networks 
Loss of cell phenotype 
(decrease glucose uptake, 
hypometabolism) 
 
Table 1: Effects of the mutations in the basement membrane core proteins due to 
diseases, on the basement membrane biophysical and biochemical properties. 
Although the conditions mentioned in Table 1 are all rare diseases a range of therapies 
are currently in clinical use. In the case of Alport syndrome (mutations affecting type IV 
collagen 3, 4, 5 chains), angiotensin-converting-enzyme inhibitors are indicated from 
the point at which patients have persistent leakage of protein into the urine. 44 However, 
these drugs only slow the progression of the disease. In a recent review, Nystrom et al. 
proposed the development of cell therapy to restore permanently the damaged BM 
proteins in order to move forward to clinical applications.90 The efficiency of such 
treatments could be tested within in vitro models before being translated to in vivo. 
III. In vitro basement membranes 
As described above, in vivo BMs are highly complex. Initial attempts to mimic these 
structures, were based on the use of simple polymer membranes but the complexity of in 
vitro membranes has been increasing over recent years.91–94  
a) Polymer membranes 
Due to their simplicity to fabricate by virtue of injection or soft-lithography, polymer 
membranes are widely used to mimic the in vivo BM within cell-based assays, particularly 
to test the BM permeability of the blood-brain barrier95,96 or the glomerulus to drugs.97 
Different polymers: (i) polycarbonate, (ii) polyester, (iii) polyethylene terephthalate 
(PET) or (iv) polytetrafluoroethylene (PTFE) are used to generate these membranes and 
different porosities are commercially available to suit the targeted applications. These 
 membranes are attached to an insert in order to be compatible with cell culture well 
plates and to be used for permeability assay for drug screening as shown in Figure 2a.  
For example, Li et al. used a type IV collagen-coated PET microporous membrane to 
reproduce the glomerular filtration barrier by culturing podocytes and endothelial cells 
on each side of the membrane (Figure 2a D). They demonstrated that type IV collagen 
coating improved cell proliferation and phenotype compared to type I collagen coating.97 
However, this model does not fully reproduce the cellular microenvironment due to the 
lack of shear stress applied to the cells. 
 
The integration of microfluidic functions within such polymer membrane-based assays 
led to the development of advanced cell-based assays, termed Organ-on-a-Chip, which 
show some promise for improving in vitro culture systems to mimic physiological 
functions. Furthermore, these assays use polydimethylsiloxane (PDMS), which is widely 
used due to its applications for rapid prototyping and microfluidics (Figure 2b). These 
devices have been widely developed and used by research groups at the Wyss 
Institute.21,98–100 Musah et al. recently generated a glomerulus-on-chip using podocytes 
derived from differentiated induced pluripotent stem cells (iPSCs) and microvascular 
endothelial cells separated by a PDMS membrane.100  This coculture, assembled in a 
bespoke microfluidic chamber, was then used to study the permeability of the barrier in 
response to drug treatment. Despite the clear advantages of using an intervening 
membrane with fabrication and integration, there may not be a faithful mimic of the 
glomerular filtration barrier in vivo. Moreover, these porous polymer membranes may 
not mimic the biophysical properties of in vivo BMs. The thickness of these membranes 
(1-10μm)101 needs to be great enough to be handled easily during the 
fabrication/integration steps. However, the thickness used is considerably higher than 
 the thickness of in vivo BMs, and this may inhibit communications between the cells 
cultured on either side of the membrane. Cell-cell communication is also affected by the 
polymer membrane topography, which is limited by the pores generated during the 
polymer membrane fabrication. The porosity limits the use of this device in migration 
assays, as the polymer membrane cannot be degraded by the trafficking cells such as 
lymphocytes. Concerning the stiffness of the porous membrane systems, they generally 
present a Young’s modulus (2.3GPa) three orders of magnitude higher than the highest in 
vivo BM Young’s modulus (~2.57MPa).62  This is also likely to influence cell phenotype. 
  
To overcome some of these biophysical issues (BM thickness and integration), Pensabene 
et al. recently demonstrated a new method to generate an ultrathin polymer membrane 
(~100nm) in poly-L-lactic acid with pattern micropores (Ø≈2μm) within a microfluidic 
device.25 They cultured human umbilical vein endothelial cells for two days, which 
attached onto the polymer membrane and displayed a good viability and spreading. 
Nevertheless, this ultrathin membrane does not exhibit in vivo-like topography and the 
Young’s modulus was not investigated. However, polymer membranes can display 
topographic patterns generated at the micro/nanoscale using hot-embossing or soft-
lithography to mimic in vivo ones.56,102 One way to generate membranes with 
physiologically relevant Young’s modulus is to use a different PDMS monomer and curing 
agent composition. Using this approach, it is possible to decrease the PDMS membrane 
Young’s modulus from 1kPa to 3MPa103,104, which is similar to in vivo BM Young’s 
modulus. Although PDMS does not exhibit the same nonlinear strain-stress behaviour 
than in vivo BMs103,105, the strain applied to the membranes within Organ-on-Chip 
improves to cell phenotype compared to those without.21,100 This result suggest that the 
cultured cells might be mainly affected by the mechanical properties of the BM coating 
 and not those of PDMS. The biochemical properties of these polymer membranes are often 
linked to the ECM components (type I or type IV collagen, BM extract such as Matrigel) 
used to functionalise them. Hong et al. recently proposed a novel method to control the 
coating on the membrane within a microfluidic device.106 Firstly, they cultured NIH/3T3 
flibroblasts on the polymer membrane in order to generate fibroblast-derived ECM 
coating before removing the fibroblasts. However, the decellularisation process seems to 
damage the secreted laminin network and so alters the biochemical properties of the 
coating. 
 
Figure 2: Different methods to use porous polymer membrane to mimic basement 
membrane. a) ECM-coated membrane insert to reproduce the glomerular filtration 
 barrier. Reproduced from Ref. 97 with the permission from Elsevier. b) Integration of 
porous polymer membrane (PDMS here) within a microfluidic device to generate a Gut-
on-a-Chip. Reproduced from Ref. 98 with the permission from the Royal Society of 
Chemistry. 
 
 
 
b) Electrospun scaffolds 
Another method to generate BM-mimicking membranes is based on polymer extrusion 
due to an applied electric field between a needle and a metallic foil. This fabrication 
method has been used to create a different kind of membrane, electrospun scaffold with 
different materials. The main interest of this method is in the generation of a network of 
polymer microfibers (Ø≈1µm), which results in a higher porosity and higher surface area 
compared to the polymer membranes described in the previous section. The polymer 
mainly used in this application is polycaprolactone (PCL), due to its biocompatibility and 
its chemical and physical properties, and different kinds of biomolecules are employed in 
order to improve cell adhesion. All these methods showed a good cell adhesion and an 
improved cell phenotype due to the functionalisation with peptides or proteins. Slater et 
al. generated a PCL scaffold on a Ni mesh with cross-linked type I collagen nanofibers in 
order to create a physiologically relevant in vitro model of the glomerulus to study its 
filtration properties in presence of drugs or disease modifiers.22  They cultured human 
conditional immortalized glomerular cells (podocytes and glomerular endothelial cells 
(GEnCs)) on each side of their scaffold. Although they did not investigate the mechanical 
and biochemical properties of their coated scaffold, the scanning electron microscope 
(SEM) images (Figure 3a) show a microfiber network on which the glomerular cells are 
lying and displaying their particular morphology and phenotype by expressing the 
 specific markers, podocin and PECAM-1 for podocytes and GEnCs respectively. Lv et al.107 
generated various scaffolds using PCL, silk fibroin and PCL/silk fibroin. The topography 
of these scaffolds with nanofibers are close to in vivo BMs as are the Young’s modulus of 
these scaffolds. To coat their scaffold, they chemically extracted some BM proteins from 
porcine mucosal tissue and coated their PCL/silk fibroin scaffold with this extract in order 
to enhance epithelial regeneration. Although they showed that the BM protein coated 
scaffold had the best results in term of cell adhesion, proliferation and phenotype, they 
did not investigate in detail the contents of this extract. Recently, Ravikrishnan et al. 
developed an electrospun PCL scaffold on which they covalently cross-linked an RGD 
peptide to study the epithelial-to-mesenchymal transition of Madin-Darby canine kidney 
cells. The scaffold they generated, exhibited a good topography to reproduce the BM. 
However, they did not characterize the biophysical properties of the scaffold and its 
biochemical properties were just defined by the cross-linked RGD peptide. Rossi et al.24 
developed a novel method to reconstruct a skin culture model that could be used to study 
drug penetration through the dermis. They engineered: (i) a star-shaped polyether 
prepolymer with ethylene glycol and propylene glycol which was statically 
copolymerized with reactive isocynate groups NCO-sP(EO-stat-PO), and added to 
poly(D,L-lactide-co-glycolide) (PLGA) before the electrospinning and (ii) different 
peptide sequences from fibronectin, type IV collagen, α1-chain of laminin and β1-chain of 
laminin. As shown in Figure 3b), the addition of the star-shaped polyether prepolymer 
helped to stabilize the electrospun scaffold compared to PLGA scaffold. Moreover, due to 
the reactive isocynate groups and the cysteine group present at the beginning of each 
peptide sequence, the peptide can be efficiently immobilised on the scaffold. The 
combination of these four peptides displayed the best performance in terms of cell 
proliferation, phenotype and secretion of ECM proteins. Compared to polymer 
 membranes, electrospun scaffolds are more physiologically relevant due to their fibrous 
aspects and their porosity. They also display a Young’s modulus (10-35MPa)24,107 one 
order of magnitude higher than the stiffness of in vivo BMs.62 However, the investigation 
of the strain-stress properties of electrospun scaffold shows that they do not display 
nonlinear stress-strain properties such as in vivo BMs and exhibit a higher shear modulus 
(~1MPa).107–109 Although they do not display specific biochemical properties, they can be 
easily coated by BM proteins such as the polymer membrane. Nevertheless, the presence 
of polymer in electrospun scaffolds limits their application because of polymer 
degradation.  
 
Figure 3: SEM images of: a) glomerular endothelial cells (A-B) and podocytes (C-D) cocultured on 
opposite sides of the collagen/PCL electrospun scaffold, scale bars=100µm (A-C), 20µm (B-D). 
 Reproduced from Ref. 22 under Creative Commons Attribution Licence. b) PLGA and 
functionalized PLGA electrospun scaffolds after 1 to 28 days in physiological buffer at 37°C, scale 
bars=5µm. Reproduced from Ref. 24 with the permission from Wiley.  
 
 
 
 
c) Peptide/polysaccharide matrices 
Different peptide/polysaccharide matrices were developed by the team led by 
Nomizu,110,111 in order to reproduce BMs. They focused on laminin as it plays a major role 
in cell maintenance. They firstly screened various peptides from 12 amino-acids 
sequences of laminin-111, which promote cell adhesion and identified the other biological 
activities of these peptides already reported in the literature. To reconstruct the physical 
properties of the BM, they used two natural polysaccharides: chitosan and alginate, which 
do not initiate immune responses. The polysaccharides are chemically activated to 
covalently bind the peptides thanks to their cysteine residue at the N-terminus. The active 
peptide sequence is separated from the N-terminus by two glycine residues. They 
demonstrated that the amount of polysaccharides influences the biological activities of 
the immobilized peptides. They then altered the concentration of two peptides 
(AG73/EF1), to identify which promoted the best cell adhesion independently of the 
polysaccharides amount. They showed that a particular ratio of these two peptides is 
critical to get a synergistic effect to improve cell attachment and spreading. Compared to 
previous methods, this approach allowed a reconstruction of a BM without any polymer 
but with polysaccharides and laminin-based peptides. Although this method is interesting 
in that it avoids the use of polymers and is easily engineered, it does not accurately reflect 
the in vivo BM because of its biochemical properties, due to the lack of other BM 
components. Even if the biophysical properties of these alginate/chitosan matrices were 
 not characterized, the literature shows the possibility of engineering a wide Young’s 
modulus range (1kPa-6MPa) and a highly porous structure, which is not fibre-like.112,113 
These matrices are useful to promote cell adhesion and phenotype in tissue engineering 
for transplantation.  
A polysaccharide matrix was also recently used by Tibbe et al. to generate a self-standing 
chitosan membrane within a microfluidic device in order to reproduce the basement 
membrane.114 Here, they formed a chitosan membrane by playing on the pH according to 
the method developed by Luo et al., who studied the permeability of their membrane with 
fluorescein, labelled antibodies and labelled nanospheres.115 Tibbe et al. then coated the 
membrane with Matrigel and seeded astrocytes on one side of the membrane. After 18h, 
they removed the chitosan membrane using a solution of acetic acid and seeded brain 
microvascular endothelial cells on the side of the membrane without cells. They showed 
that the astrocyte morphology is not altered by the membrane removal. The main 
advantage of this method is its direct integration within a microfluidic device, which can 
help to maintain the sterility of the device. To conclude on these polysaccharide matrices, 
they present various interesting properties such as their tuneable Young’s modulus, their 
natural origin and their ability to be functionalised.   
 
d) Extracellular matrix protein gel 
This method is widely used in cell-based assays, as it is the one of simplest ways to mimic 
the BM in vitro. It consists of a layer of extracellular matrix protein between the two cell 
types cultured in the well plate. It was introduced in 1989 by Dunn et al., who cultured 
primary rat hepatocytes between two thick layers from a type I collagen gel in order to 
reproduce the hepatic basement membrane and enhance hepatocytes polarization.116 
They were able to culture the primary cells for 42 days with a good normalized albumin 
 secretion but the total amount of DNA decreases by two times between the beginning and 
the end of the culture. This pioneering work suffers from several limitations such as the 
collagen gel thickness restricting the nutrient diffusion to the cells and the gel 
composition consisting of only type I collagen, which is not a major component of the in 
vivo BM. In parallel to this work, at the end of the 1980s, a number of groups, led by Timpl 
and Martin, attempted to understand the biochemical effects of the BM components and 
their interactions with the neighbouring cells.15,117–120 This work led to a better 
understanding of the complex composition and structure of the BM and Kleinman et al.118 
developed a gel made of BM proteins from Engelbreth-Holm-Swarm murine sarcoma, 
which was studied by Orkin et al.119 This gel, now known as Matrigel, is composed of type 
IV collagen (α1α1α2 isoform), laminin (α1β1γ1 isoform), nidogens, heparan sulphate 
proteoglycans and a number of growth factors such as FGF, EGF, TGFβ, IGF and PDGF (it 
also exists with reduced growth factors).121 Matrigel has been used to reconstruct the BM 
and to increase the relevance of hepatocyte culture122,123, mammary cells124,125, prostate 
cells126 or cancer cells.121 Arends et al. used different commercially available BM protein 
gels and investigated the effects of their biochemical properties on their biophysical 
properties.127 They demonstrated not only that the composition of these gels especially 
the nidogen concentration, is very different in each gel according to the manufacturer 
process but also that the gel composition affects its topography and its Young’s modulus. 
Furthermore, they showed that the cell migration (human promyelocytic leukemia cell 
line HL-60) in the gel depends on its composition.  BM protein gels like Matrigel are 
actually one of the best in reproducing the BM in cell-based assays as it is composed of 
only biomolecules but like the other methods described above it suffers from a couple of 
disadvantages. Firstly, due to its tumorigenic origin, its components and their 
concentration cannot reproduce accurately the desired BM and they display batch-to-
 batch variation. Secondly due to its physical state, it is difficult to integrate them in 
advanced cell-based assays such as organs-on-chip without polymer membranes.10 To 
overcome this integration issue, Takezawa and co-authors proposed a novel scaffold of 
type I collagen vitrigel, which is maintained by a silk fibre network or a nylon membrane 
ring128, in order to reconstruct the BM of various organs such as the kidney129, the liver130 
and the eyes.131 Toh et al. reconstructed a collagen barrier to mimic the basement 
membrane within a microfluidic device.132 They studied the migration of breast cancer 
cells (MX-1) through collagen barrier although without further characterisation. 
 
Figure 4 : Different methods to generate an extracellular matrix gel-based basement 
membrane: a) Reproduction of the Descemet’s membrane with a thin type IV 
collagen/laminin membrane and a thick type I collagen membrane. Reproduced from Ref. 
 133 with permission from Wiley. b) Generation and integration of an extracellular matrix 
membrane within a microfluidic device for Organ-on-Chip applications. Reproduced from 
Ref. 27 with permission from the Royal Society of Chemistry. 
More recently, Palchesko et al. proposed a novel engineered BM composed of type I 
collagen, type IV collagen and laminin to replace the Descemet’s membrane in the corneal 
endothelium regeneration.133 This membrane whose fabrication process is described in 
Figure 4a), exhibits a fibrous aspect according to the atomic force microscopy analysis. 
They showed that this membrane promotes cell adhesion, cell density and cell-cell tight 
junctions. Interestingly, they demonstrated that the cells cultured on this membrane 
secrete a laminin isoform, which does not match with the isoform initially present in the 
membrane. Despite its thickness and its unknown Young’s modulus, this membrane 
provides a good material to reproduce a few of the properties of in vivo BMs (topography, 
cell phenotype).  
 
Mondrinos et al. were the first to design a membrane made of only ECM proteins, which 
can be integrated within a microfluidic device (Figure 4b).27 They studied the physical 
properties of the membrane and its effects on the cellular phenotypes using different 
mixtures of ECM components: (i) type I collagen, (ii) type I collagen and Matrigel or (iii) 
type I collagen and alginate by using a PDMS stab. They found with scanning electron 
microscopy that the membranes look like randomly oriented fibres forming a dense 3-D 
scaffold. They measured the thickness of their membrane (~20μm) and the Young’s 
modulus of their membrane to compare with in vivo BMs. The Young’s modulus of these 
membranes can be tuned according to type I collagen/Matrigel ratio from 429 to 660kPa.  
However, they did not investigate if this ECM blend exhibit a stress-stiffening property as 
type I collagen display one but not Matrigel.63 To generate an Organ-on-Chip device, they 
 peeled off their membrane from the PDMS stab to insert it within a microfluidic chamber. 
They showed, using a permeability assay that the main difference between the ECM-made 
membranes is due to the presence of alginate creating larger pores. The permeability of 
20kDa FITC-dextran of the collagen/alginate membrane is similar to a transwell 
membrane and higher than the collagen and collagen/Matrigel membranes. To assess the 
phenotype of cells cultured on the ECM membrane, they analysed the phosphorylation of 
focal adhesion kinase (pFAK) in human umbilical vein endothelial cells (HUVECs). The 
pFAK levels in the case of collagen/Matrigel membrane were more than nine times higher 
than the levels seen for the transwell membrane. Furthermore, they were able to culture 
different cell types, exhibiting a good viability, within the microfluidic device to mimic a 
lung-on-chip device. More recently, Humayun et al. proposed a novel method to generate 
an in vitro BM within a microfluidic device using a suspended hydrogel based on type I 
collagen and Matrigel mixture.134 Interestingly, they demonstrated that the mixture with 
the highest Matrigel concentration give the best results in term of cell adhesion.  
 
These latest works pave the way for further integration of a constructed representative 
BM within a microfluidic organs-on-chip by reproducing a good model of the BM without 
any polymer. However, there are still several drawbacks:  
(i) Even though this membrane is only made of ECM components, it still does not 
accurately reflect the composition of in vivo BMs as type I collagen is a major 
component of this in vitro BM and Matrigel contains only some isoforms as previously 
mentioned. 
(ii) The membrane thickness (~20μm) is higher than those in vivo. 
(iii) Due its thickness, the membrane needs to be very carefully peeled off from the PDMS 
stub and inserted within the microfluidic device.  
  
 
 
e) Layer-by-layer coculture 
The easiest method to reproduce the relevant BMs relies on the secretion of ECM 
components by the layer-by-layer cocultured cells. As the different cell types secrete 
different components of the BM135, various combinations of cells have been cultured such 
as keratinocytes/fibroblasts136, Sertoli cells/Testis peritubular cells137, Caco-2/intestinal 
mesenchymal cells138, hepatocytes/liver endothelial23 and podocytes/glomerular 
endothelial cells139 without any layer between the two cell layer. The beneficial effect of 
coculture on the BM formation has been also proved when hepatocytes are cultured with 
liver endothelial cells (Figure 5a), especially when the cell oxygenation is well 
perfomed.23 This coculture enhances cell phenotype through the expression of specific 
markers and the formation of bile canaliculi and keeps a proper cell viability over two 
weeks. Although it is possible to assess BM formation using histochemistry, it has also 
been demonstrated using immunofluorescence staining to show the different 
components of the BM (mainly type IV collagen or laminin isoforms).138,139 
  
Figure 5 : Characterisation of the coculture effect on cell phenotype and viability. a) 
Viability and ECM staining of primary rat hepatocytes cultured with liver endothelial cells 
(TMNK-1) in low oxygenated (O2- culture) and well-oxygenated culture system (O2+ 
culture). Adapted from Ref. 23 with permission from the Royal Society of Chemistry. b) 
Immunohistochemistry images of the BM components present in keratinocyte culture 
onto fibroblast-free collagen matrices (1) and onto matrices containing 1 x 105 
fibroblasts/mL collagen (2).  Adapted from Ref. 136 with permission from Elsevier. The 
original figure136 was published in Journal of Investigative Dermatology, Vol. 124, 
Abdoelwaheb El Ghalbzouri, Marcel F. Honkman, Remco Dijkman, Maria Ponec, Basement 
 Membrane Reconstriction in Human Skin Equivalents is Regulated by Fibroblasts and/or 
Exogenously Activated Keratinocytes, 79-86, Copyright the Society for Investigative 
Dermatology, 2005. 
The layer-by-layer coculture reproduces the BM biochemical properties in a 
physiologically relevant manner as it helps to better maintain the cellular phenotype than 
a simple overlay of ECM gel due to the secretion of not only BM components but also 
signalling molecules by the cells. To improve this technique, several research groups have 
included a layer of ECM protein gel140,141 or used polyelectrolyte layers 
(chitosan/hyaluronic acid).142–144 For example, El Ghalbzouri et al. demonstrated that 
fibroblast/keratinocyte coculture enhances the secretion of BM components compared to 
single culture of keratinocytes as illustrated in Figure 5b (1: keratinocytes culture, 2: 
coculture).136  The expression of various BM components clearly shows the importance of 
cross talk between cells for BM formation. However, the addition of this layer can change 
the BM biophysical properties and to date there is no proof of BM remodelling. The layer-
by-layer coculture has two major advantages: (i) its compatibility with bioprinting, which 
increases the complexity of the culture system by generating a specific pattern with 
various cell types145–148 and (ii) the possibility to use cell sheet engineering to generate a 
complex sheet of cells thanks to a thermo-sensible polymer.149,150 This cell sheet method 
can be used to integrate the cocultured cells in an advanced cell-based assay. 
Nevertheless, its integration within a microfluidic device can be quite challenging in order 
to keep the structure of the cell layer and its sterility. 
 
IV. Applications of in vitro basement membranes 
 As we described in the section II, in vivo BMs are generated by a complex self-assembly of 
various biomolecules, creating a dynamic 3-D matrix. Due to the difficulty in mimicking 
this dynamic in vivo behaviour in in vitro systems, the current models only simulate some 
of the specific functions of the BM. The limitations of these in vitro BMs are mainly due to 
material issues.10 In order to perform a given function related to the BM within an 
advanced coculture cell-based assay, a trade-off has to be made between the material 
needed for the function and the ease of integrating the material into the required system. 
This trade-off will be discussed in this section, particular for coculture cell-based assays 
applied to drug screening and disease modelling.  Table 2 summarizes the capacity of 
each of the materials (described in the previous section) in terms of properties, 
integration and applications. 
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Table 2:  Capability of the different in vitro methods to reproduce in vivo BM features 
(biophysical and biochemical), to be engineered for complex functions and used for drug 
screening and disease modelling (: very convenient, : convenient : limited, : 
very limited) 
a) Drug screening 
 The development of a new drug requires not only validation of drug efficiency but also 
measurements of its pharmacokinetic and pharmacodynamics properties including entry 
and elimination from target cells. Coculture cell-based assays for drug screening should 
enable the permeability of the BM-mimicking material and cells to biomolecules to be 
quantified as well as cell viability. A simple model with a BM extract-coated porous 
polymer membrane can be sufficient to reproduce the BM within permeability assays. Li 
et al. studied the permeability of their coculture system to albumin.97 They demonstrated 
that without cells the uncoated membrane is more permeable than a collagen-coated 
membrane and that GEnCs seems to provide the largest contribution to albumin 
retention. This is probably due to  the fenestrae and glycocalyx formed by the endothelial 
cell.151 They also investigated the effect of drugs targeting the podocytes or the GEnCs on 
albumin permeability. However, their system was restricted to a static analysis, as it did 
not integrate a microfluidic circuit. To improve the capability of these assays, two 
different research groups, one in the USA and the other in China developed microfluidic 
devices based on porous polymer membrane-mimicking BM.26,100 Musah et al. 
demonstrated that their iPSC-derived podocytes cocultured with GEnCs enhanced the 
albumin retention compared to a culture of GEnCs only.100 This result contradicts the 
findings in the static culture discussed above. The reason for this difference might be due 
to differences in the distribution of type IV collagen, which is mainly generated by GEnCs 
in static conditions and by podocytes when mechanical strain is applied.100  
 
Zhou et al.  cultured rodent GEnCs and podocytes within a microfluidic device.  They 
confirmed that the coculture improves the permeability resistance as assessed using 
labelled inulin, bovine serum albumin and IgG. Their data showed that the contribution of 
GEnCs to the permeability resistance is more important than of podocytes but in this 
 system, there is no information concerning the BM components secreted by the cultured 
cells.  
 
An explanation of these discrepancies in the literature might be due the stiffness of the 
polymer membrane mimicking the BM and show the importance of the choice of material. 
For drug screening, in particular permeability assays, the model requires the generation 
of two different compartments separated by the BM-mimicking material. This separation 
depends on a material that can be easily handled and has a high mechanical strength. For 
these reasons, porous polymer membranes are widely employed in permeability assays. 
Although yet to be used, electrospun scaffolds might be a good candidate for this type of 
assay due to their topography and the possibility of engineering their biochemical 
properties. Although their integration was quite limited, the best candidate is probably an 
ECM protein gel-based membrane due to their biochemical properties and composition.  
 
b) Disease modelling 
Various disease processes result in the modification of BM biophysical and/or 
biochemical properties. These modifications can be due to BM thickening, the 
modification of the BM microenvironment (e.g. hypertension, diabetes), BM invasion by 
cancer cells or the mutation of a BM component gene (see table 1). All these parameters 
make in vitro disease models strongly dependent not only on the materials used to mimic 
the BM but also on the coculture cell-based assay design. Diseases that are due to changes 
in the BM microenvironment are the easier to model, particularly in coculture cell-based 
assays integrating microfluidics. Zhou et al. developed a device to mimic hypertensive 
nephropathy, assuming that higher blood pressure induces higher blood flow rate.26 They 
demonstrated that high flow rate (15µL/min) increases the protein permeability and 
 damages the cell phenotype of both podocytes and GEnCs. Although these interesting 
results were confirmed by in vivo measurements, their device is limited by the non-
physiologically relevant properties of their BM-mimicking polycarbonate membrane. 
Indeed, polycarbonate displays a Young’s modulus of 2.5GPa152, which is three order of 
magnitude higher than that seen in vivo. Furthermore, they did not calculate the value of 
the shear stress applied to the cells. The BM extract used to coat the polycarbonate 
membrane, is from EHS tumour, which can contain irrelevant biochemical cues.  
 
To study cancer progression from endothelial-mesenchymal transition (EMT) to the 
cancer cell adhesion, invasion and vascularisation, various in vitro cancer models have 
been developed. 77,78,140,153,154 Nevertheless, the generation of a good advanced cell-based 
assay to model cancer still remains challenging as it depends on both biophysical and 
biochemical properties of BMs. Kamm’s group at the Massachusetts Institute of 
Technology, has been developing advanced cell-based assays to study cancer progression. 
They demonstrated that cancer progression is affected by various biophysical and 
biochemical cues.155–158 However, the relevance of their device is limited because of the 
use of type I collagen to reproduce the BM instead of type IV collagen and laminin.  
To study the effect of BM components, Walter et al. demonstrated using a type IV collagen-
coated polyacrylamide gel that physical defects within the type IV collagen network 
triggers EMT, causes MMP-9 inhibition and changes BM stiffness due to the lack of type 
IV collagen degradation suggesting the beginning of a fibrosis like behaviour.159 They also 
generated a type IV collagen-coated type I collagen gel and showed that cells were able to 
invade the type I collagen gel after undergoing through EMT due to the defects within the 
type IV collagen network. This work shows the importance of the BM biophysical 
properties in mechanotransduction/mechanoactivation for cancer research. The authors 
 acknowledge the limitations of their model due to the lack of BM biochemical cues, 
especially those from the laminin network. However, they showed the importance of MMP 
inhibition/activation in such cancer models.  
 
The major role of the proteinases suggests that models using polymer membranes or 
electrospun scaffolds are not a good choice, as they generally cannot be degraded by 
proteinases. Furthermore, another important consequence of the proteinase activity is 
the generation of peptidic fragments called matricryptins, which can exhibit various 
bioactivities either physiological or pathological.160–163 To study these effects, the use of 
only ECM components is required to mimic the BM behaviour. For example, Horejs et al. 
developed a electrospun scaffold containing a fragment of the laminin β1-chain.164 They 
demonstrated the potential of this fragment to modulate MMP expression and activity. In 
using only BM components, Mondrinos et al. integrate a performed spheroid of human 
lung adenocarcinoma cells within their microfluidic device. Although they demonstrated 
the spheroid adhesion on their membrane, they did not investigate BM invasion and show 
that their type I collagen membrane is resistant to cell-mediated proteolytic 
degradation.27  
 
Commercially available ECM components from BM extracts have their own limitations 
because they are specific isoforms of BM components. They can have different 
biochemical activities due to the generation of different fragments and the remodelling 
also depends on the surface properties of the material, which support the ECM 
components.165,166 For this reason, the rational for the used ECM components mainly 
depends on the targeted objectives. In the case of in vitro model to mimic diseases due to 
BM component mutation, its generation is still very difficult because of the limited 
 availability of these mutated components. The development of iPSC technology using cells 
from patients in order to generate specific BM components is a promising new method to 
model disease within cell-based assays. 
 
V. Conclusions and future prospects 
In vivo basement membranes are complex biological structures, which performs various 
functions by virtue of their specific components. Furthermore, they display a dynamic 
behaviour, which is not yet fully understood. For this reason, all the BM functions are not 
only difficult to recapitulate from both a biophysical and biochemical perspective, but are 
challenging to integrate in cell-based assays. These assays are generally limited by the low 
functionalities of the BM-mimicking materials that are used. Currently, the best BM 
mimics seem to be the functionalized electrospun scaffold and the extracellular matrix 
membrane, such as those introduced by Rossi et al.24 and Mondrinos et al.27, respectively. 
These both reproduce the biophysical properties of in vivo BMs, except the nonlinear 
mechanical properties. On the electrospun scaffold developed by Rossi and co-workers24, 
the biochemical properties could be tuned by changing the nature of the peptide used. 
Furthermore, the relative robustness of the scaffolds make them easier to integrate within 
microfluidic assays. In contrast, extracellular matrix membranes are more difficult to 
integrate into devices due to their fragile nature, but their offer advantageous in 
applications such as BM invasion studies. 
 
Future improvements of engineered BMs for coculture cell-based assays will mainly 
depend on the targeted applications. Applications, in which BM composition is important, 
such as genetic disorders of BM, will require the development of recombinant BM 
components and/or the generation of differentiated relevant cells from patient-derived 
 iPSCs. Applications related to the blood pressure will need a BM-mimicking material, 
which exhibits nonlinear mechanical properties. For this purpose, the integration of 
hydrogels, which display stress-stiffening effect167,168, can be a good solution. However, 
their biochemical properties will have to be improved by integrating specific BM peptides, 
for example. Further models integrating both biophysical and biochemical BM properties 
will not only help to study the contributions of each BM components and their correlation 
but also to get a better understanding of the drug diffusion through BMs and BM-related 
diseases. This will enable the development of new drugs and/or the identification of new 
biomarkers. 
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